Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Rayner

Showing results (401-410 of 422) with videos related to

Pageof 43
Sort By:
Diabetes|October 4, 2013
Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemiaMahesh M Umapathysivam, Michael Y Lee, Karen L Jones, et al.
Igie : Innovation, Investigation and Insights|February 6, 2026
Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinomaAmanda Huoy Wen Lim, Nimit Singhal, Dylan Bartholomeusz, et al.
Diabetes|October 17, 2015
The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled TrialSony S Thazhath, Chinmay S Marathe, Tongzhi Wu, et al.
Diabetes Care|November 10, 2020
Erratum. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2020;43:1813-1821Christopher K Rayner, Linda E Watson, Liza K Phillips, et al.
Diabetes Care|May 31, 2020
Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled TrialChristopher K Rayner, Linda E Watson, Liza K Phillips, et al.
Critical Care Medicine|August 22, 2013
The effects of critical illness on intestinal glucose sensing, transporters, and absorptionAdam M Deane, Chris K Rayner, Alex Keeshan, et al.
Acta Anaesthesiologica Scandinavica|December 15, 2016
Occult upper gastrointestinal mucosal abnormalities in critically ill patientsC Ovenden, M P Plummer, S Selvanderan, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrationsKaren L Jones, Lian Q Huynh, Seva Hatzinikolas, et al.
The American Journal of Clinical Nutrition|May 11, 2012
Randomized double-blind crossover study to determine the effects of erythromycin on small intestinal nutrient absorption and transit in the critically illAdam M Deane, Gerald L Wong, Michael Horowitz, et al.
Nutrients|July 8, 2020
Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric DistributionRyan Jalleh, Hung Pham, Chinmay S Marathe, et al.
Pageof 43

Showing results (401-410 of 422) with videos related to

Sort By:
Pageof 43
Diabetes|October 4, 2013
Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemiaMahesh M Umapathysivam, Michael Y Lee, Karen L Jones, et al.
Igie : Innovation, Investigation and Insights|February 6, 2026
Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinomaAmanda Huoy Wen Lim, Nimit Singhal, Dylan Bartholomeusz, et al.
Diabetes|October 17, 2015
The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled TrialSony S Thazhath, Chinmay S Marathe, Tongzhi Wu, et al.
Diabetes Care|November 10, 2020
Erratum. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2020;43:1813-1821Christopher K Rayner, Linda E Watson, Liza K Phillips, et al.
Diabetes Care|May 31, 2020
Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled TrialChristopher K Rayner, Linda E Watson, Liza K Phillips, et al.
Critical Care Medicine|August 22, 2013
The effects of critical illness on intestinal glucose sensing, transporters, and absorptionAdam M Deane, Chris K Rayner, Alex Keeshan, et al.
Acta Anaesthesiologica Scandinavica|December 15, 2016
Occult upper gastrointestinal mucosal abnormalities in critically ill patientsC Ovenden, M P Plummer, S Selvanderan, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrationsKaren L Jones, Lian Q Huynh, Seva Hatzinikolas, et al.
The American Journal of Clinical Nutrition|May 11, 2012
Randomized double-blind crossover study to determine the effects of erythromycin on small intestinal nutrient absorption and transit in the critically illAdam M Deane, Gerald L Wong, Michael Horowitz, et al.
Nutrients|July 8, 2020
Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric DistributionRyan Jalleh, Hung Pham, Chinmay S Marathe, et al.
Pageof 43